Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Protagonist Therapeutics (PTGX) Non Operating Income: 2016-2024

Historic Non Operating Income for Protagonist Therapeutics (PTGX) over the last 9 years, with Dec 2024 value amounting to $250,000.

  • Protagonist Therapeutics' Non Operating Income fell 76.60% to $33,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $182,000, marking a year-over-year decrease of 30.80%. This contributed to the annual value of $250,000 for FY2024, which is 224.38% up from last year.
  • Latest data reveals that Protagonist Therapeutics reported Non Operating Income of $250,000 as of FY2024, which was up 224.38% from -$201,000 recorded in FY2023.
  • Over the past 5 years, Protagonist Therapeutics' Non Operating Income peaked at $250,000 during FY2024, and registered a low of -$201,000 during FY2023.
  • Its 3-year average for Non Operating Income is -$10,333, with a median of -$80,000 in 2022.
  • Its Non Operating Income has fluctuated over the past 5 years, first slumped by 4,500.00% in 2020, then surged by 224.38% in 2024.
  • Yearly analysis of 5 years shows Protagonist Therapeutics' Non Operating Income stood at -$46,000 in 2020, then plummeted by 223.91% to -$149,000 in 2021, then spiked by 46.31% to -$80,000 in 2022, then tumbled by 151.25% to -$201,000 in 2023, then skyrocketed by 224.38% to $250,000 in 2024.